You just read:

New Results add to Growing Body of Evidence That Support Bendamustine-rituximab (B-R) Combination as First-Line Treatment in Patients With Indolent non-Hodgkin (iNHL) and Mantle Cell Lymphomas (MCL)

News provided by

Mundipharma International

11 Dec, 2012, 12:30 GMT